NANO₂
NanO₂ was designed to increase oxygen delivery in the body, aiming to reverse tissue hypoxia.
Hypoxia happens when the body’s cells cannot get enough oxygen, and it plays a critical role in the progression of many diseases even causing death. Our goal is to reverse tissue hypoxia, the root cause for death, injury, and resistance in treatment in these diseases.
After IV infusion, NanO₂ forms nanodroplets inside the body.
These droplets pick up oxygen from the lungs and deliver it to the cells that need it.
The active pharmaceutical ingredient (API) of NanO₂ is then exhaled and not metabolized.
Clinical Studies
NuvOx Therapeutics is conducting clinical trials in Glioblastoma, Stroke, and Respiratory Distress to evaluate the safety and efficacy of NanO₂. Please click the links below to learn more.
NanO₂ is under clinical investigation and not yet approved for general medical use.
RECRUITING
Glioblastoma Phase IIb
The RESTORE Study is recruiting in the United States for patients with newly diagnosed Glioblastoma.